Document ID: FDA-2012-N-0001-0051
Agency: fda
Document Type: Notice
Title: Nonvoting Industry Representatives; Notification and Nominations Request: Blood Products Advisory Committee
Posted Date: 2012-04-12T04:00Z

[Federal Register Volume 77, Number 71 (Thursday, April 12, 2012)]
[Notices]
[Pages 21982-21983]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-8823]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0001]

Request for Notification From Industry Organizations Interested 
in Participating in the Selection Process for Nonvoting Industry 
Representative on the Blood Products Advisory Committee, and Request 
for Nominations for Nonvoting Industry Representatives on the Blood 
Products Advisory Committee

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting that any 
industry organizations interested in participating in the selection of 
a nonvoting industry representative to serve on the Blood Products 
Advisory Committee for the Center for Biologics Evaluation and Research 
(CBER) notify FDA in writing. FDA is also requesting nominations for a 
nonvoting industry representative to serve on the Blood Products 
Advisory Committee. A nominee may either be self-nominated

[[Page 21983]]

or nominated by an organization to serve as a nonvoting industry 
representative. Nominations will be accepted for current vacancies 
effective with this notice.

DATES: Any industry organization interested in participating in the 
selection of an appropriate nonvoting member to represent industry 
interests must send a letter stating that interest to FDA by May 14, 
2012, for the vacancy listed in this notice. Concurrently, nomination 
materials for prospective candidates should be sent to FDA by May 14, 
2012.

ADDRESSES: All letters of interest and nominations should be submitted 
in writing to Bryan Emery (see: FOR FURTHER INFORMATION CONTACT).

FOR FURTHER INFORMATION CONTACT: Bryan Emery, Center for Biologics 
Evaluation and Research, Food and Drug Administration, 1401 Rockville 
Pike (HFM-71), Rockville, MD 20852-1448, 301-827-1277, Fax: 301-827-
0294, email: bryan.emery@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The Agency intends to add a nonvoting 
industry representative to the following advisory committee:

I. Blood Products Advisory Committee for the Center for Biologics 
Evaluation and Research

    Members are selected by the Commissioner of Food and Drugs (the 
Commissioner) or designee from among authorities knowledgeable in the 
fields of clinical and administrative medicine, hematology, immunology, 
blood banking, surgery, internal medicine, biochemistry, engineering, 
biological and physical sciences, biotechnology, computer technology, 
statistics, epidemiology, sociology/ethics, and other related 
professions.

II. Selection Procedure

    Any industry organization interested in participating in the 
selection of an appropriate nonvoting member to represent industry 
interests should send a letter stating that interest to the FDA contact 
(see FOR FURTHER INFORMATION CONTACT) within 30 days of publication of 
this document (see DATES). Within the subsequent 30 days, FDA will send 
a letter to each organization that has expressed an interest, attaching 
a complete list of all such organizations; and a list of all nominees 
along with their current resumes. The letter will also state that it is 
the responsibility of the interested organizations to confer with one 
another and to select a candidate, within 60 days after the receipt of 
the FDA letter, to serve as the nonvoting member to represent industry 
interests for the committee. The interested organizations are not bound 
by the list of nominees in selecting a candidate. However, if no 
individual is selected within 60 days, the Commissioner will select the 
nonvoting member to represent industry interests.

III. Application Procedure

    Individuals may self nominate and/or an organization may nominate 
one or more individuals to serve as a nonvoting industry 
representative. Contact information, a current curriculum vitae, and 
the name of the committee of interest should be sent to the FDA contact 
person (see FOR FURTHER INFORMATION CONTACT) within 30 days of 
publication of this document (see DATES). FDA will forward all 
nominations to the organizations expressing interest in participating 
in the selection process for the committee. (Persons who nominate 
themselves as nonvoting industry representatives will not participate 
in the selection process).
    FDA has a special interest in ensuring that women, minority groups, 
individuals with physical disabilities, and small businesses are 
adequately represented on its advisory committees, and therefore, 
encourages nominations for appropriately qualified candidates from 
these groups. Specifically, in this document, nominations for nonvoting 
representatives of industry interests are encouraged from the blood and 
blood products manufacturing industry.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: April 9, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2012-8823 Filed 4-11-12; 8:45 am]
BILLING CODE 4160-01-P